Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study).

Trial Profile

Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2013

At a glance

  • Drugs Aspirin/dipyridamole (Primary) ; Omeprazole
  • Indications Duodenal ulcer; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Peptic ulcer; Stroke; Thrombosis; Transient ischaemic attacks
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2012 Results have been presented at the 2012 International Stroke Conference according to a Boehringer Ingelheim media release. Results were also reported in the media release.
    • 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top